-

$undefined

N/A

(N/A)

Bicara Therapeutics :BCAX Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

Location: Cambridge, Massachusetts, United States | Website: https://www.bicara.com | Industry: | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

303.8M

Cash

489.7M

Avg Qtr Burn

-18.69M

Short % of Float

19.00%

Insider Ownership

0.43%

Institutional Own.

85.72%

Qtr Updated

12/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ficerafusp alfa + Pembrolizumab Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ficerafusp alfa Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.